Dear Health Care Provider:

RE: 2016-2017 Season for Respiratory Syncytial Virus Prophylaxis for High-Risk Infants

This letter details the Respiratory Syncytial Virus (RSV) Prophylaxis for High-Risk Infants Program (the “Program”).

Links to the following can be found on the [Program’s webpage]:
- Enrolment Form,
- Synagis® Order Form,
- Enrolment and Drug Ordering Process
- Frequently Asked Questions

Updates for the 2016-2017 RSV Prophylaxis Season:

Enrolment Form
The table below outlines additional information that is being requested for the upcoming season. This information will enable the form to be a more detailed clinical record of the patient’s eligibility for RSV prophylaxis and may assist the Program adjudicators in making a funding decision. Of note, the Ministry is requesting that the Risk Assessment Tool be completed for all infants born 33 to 35 completed weeks gestation, even if eligible under other criteria.

<table>
<thead>
<tr>
<th>Applicable Section of Form</th>
<th>Additional information required on the enrolment form</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 1</td>
<td>Date of submission</td>
</tr>
<tr>
<td>Section 1</td>
<td>Gestational age at birth</td>
</tr>
<tr>
<td>Section 4</td>
<td>Complete Risk Assessment Tool for all infants 33 - 35 completed weeks gestation</td>
</tr>
<tr>
<td>Section 5</td>
<td>Hospital where diagnosis was made for children with congenital heart disease (CHD)</td>
</tr>
<tr>
<td>Section 6</td>
<td>Specify the medical illness being considered under Special Clinical Circumstances in the space provided</td>
</tr>
</tbody>
</table>

Synagis® Order Form
This form has been revised and enhanced with embedded tools to support and facilitate the drug ordering process.
New formulation of palivizumab (solution for injection)
AbbVie has introduced palivizumab solution for injection for the 2016-2017 season. The new formulation is available in single-use vials containing 0.5 mL or 1.0 mL of solution for injection, both with a concentration of 100 mg/mL. This new formulation does not have to be reconstituted before use. Clinics or physician offices with remaining stock of palivizumab lyophilized powder are reminded to use up this stock since unused vials cannot be returned to AbbVie. Please note that the solution for injection and lyophilized powder formulations should not be mixed.

Additional information regarding palivizumab can be found on page 4.

Enrolment Criteria for Approval:

For an infant to be eligible for the Program, the infant must be an Ontario resident with a valid Ontario health card and satisfy the criteria as recommended by Ontario’s RSV Advisory Group. The funding criteria remain unchanged from the previous season and are listed on the enrolment form as follows:

- Infants born prematurely at ≤ 32 completed weeks gestation and aged ≤ 6 months at the start of, or during, the local RSV season; or
- Infants 33 – 35 completed weeks gestation and aged ≤ 6 months at the start of, or during the local RSV season, who DO NOT live in isolated communities AND have a Risk Assessment Tool Score of 49 to 100; or
- Infants 33 – 35 completed weeks gestation and aged ≤ 6 months at the start of, or during the local RSV season and who LIVE IN isolated communities where pediatric hospital care is not readily accessible and ambulance transportation is required for hospital admission; or
- Children < 24 months of age with bronchopulmonary dysplasia/chronic lung disease (BPD/CLD) and who required oxygen and/or medical therapy within the 6 months preceding the RSV season; or
- Children < 24 months of age with hemodynamically significant cyanotic or acyanotic congenital heart disease (CHD), requiring corrective surgery or are on cardiac medication for hemodynamic significant disease; or
- Children < 24 months of age with Down Syndrome/Trisomy 21, with or without hemodynamically significant congenital heart disease.

Multiple Birth Sets:

If a high-risk infant of a multiple birth set is approved for the season, the siblings in the same set are also eligible for prophylaxis. Enrolments for the siblings in the same multiple birth set should be submitted on a separate form at the same time as the high-risk infant - irrespective of the discharge date(s) of the individual infants. Under Section 1 of the form, please specify the set (e.g. twins, triplets) and provide the multiple number (e.g. child 1, 2, 3) in the box titled, “Multiple Birth Infant Number”. Although there is no specific space available on the form, you may also wish to indicate the Reference Number of the approved infant of the multiple birth set, if available.

Consideration of Special Clinical Circumstances:
Infants who are over 2 years of age at the start of the active RSV season will not be approved for funding. However, enrolment requests for high-risk infants who do not satisfy the above criteria will be considered by the Ministry’s medical experts in RSV prophylaxis. These enrolment requests must include a letter from the requesting physician stating the infant’s specific medical illness and detailing the clinical rationale AND a supporting letter from an infectious disease specialist, neonatologist or a respirologist. If a supporting letter cannot be obtained because of limited accessibility to the above specialists, this should be clearly stated on the enrolment form.

Please note that your letter must provide sufficient clinical details as it relates to the patient and the risk for severe RSV disease. The request will then be considered by the Ministry’s expert clinicians in RSV who may contact the requesting physician for additional information. When providing clinical findings/status of the child, please be as fulsome as possible to avoid delays in the review process. It is important that no personal health identifiers (e.g. infant’s name, address, health card number, and parents’ names) be provided on the supporting letters.

To assist the Ministry’s expert clinicians in contacting the requesting physician if required, please include a direct phone line (back-office number) on the enrolment form, if available.

Season Start and End:

Start
Due to the seasonality of the RSV virus, palivizumab should only be administered during the active RSV season which for eastern, central and southern Ontario generally occurs from mid-November to March of the following year. As such, Ontario’s RSV Advisory Group is recommending that the first dose be administered to eligible infants on or after the week of November 21st.

For northern Ontario (e.g. Sudbury and further north), the RSV season generally starts later in the year (e.g. December or January) and correspondingly, the end of the season may be delayed (e.g. April or May).

End
For most of Ontario, the prophylaxis season will finish at the end of March. However, if continued prophylaxis is required on or after April 1st OR if regional RSV activity persists, the requesting physician must confirm the RSV activity level in the infant’s area of residence. The status of the regional activity must be stated on the request as per the definition below.

Regional activity can be confirmed by contacting the local or regional hospital’s pediatric infectious disease department to inquire on the status of the season. The RSV season is considered on-going when there are TWO or more LOCAL RSV related hospitalizations per week for two consecutive weeks (Law et al. 2004).

The Ministry will communicate to the community the official start date and a declaration to the end to the RSV season.

Dosing Interval:

The interval between the 1st and 2nd dose should be 21-28 days.
The intervals between the 2nd, 3rd, 4th, and 5th doses should be 28-35 days.

Based on human pharmacokinetic modeling, the 5th dose of palivizumab will provide sufficient antibody levels to protect for at least 6 weeks. **As such, the 5th dose will provide the child protection through the end of April or into the month of May if the usual dosing schedule is followed.**

The Program covers the cost of up to five (5) doses of palivizumab administered during the active RSV season to infants at high-risk for RSV infection. A sixth dose will NOT be covered by the Program except in isolated circumstances which will require approval by the Ministry. These requests should be submitted to AbbVie as per the usual process and will be adjudicated by the Ministry.

**Palivizumab (Synagis®):**

Palivizumab is a monoclonal antibody that provides passive immunization against the RSV virus and is not expected to interfere with routine vaccinations. However like other vaccinations, palivizumab has the potential to induce an adverse event including but not limited to fevers. For proper monitoring of adverse events, palivizumab can be administered 24 hours before or after a routine vaccination.

Immunization practices that are described in the [Canadian Immunization Guide](#) should be followed. Part I of the Guide titled “Key Immunization Information” identifies these practices in the section “National Guidelines for Immunization Practices”. In addition, it is important to document the respective lot numbers of doses of palivizumab that are administered to patients.

The costs of 50 mg and 100 mg vials of palivizumab are $752.26 and $1,504.51, respectively. The Ministry requests that all health care providers be mindful of the costs such that drug wastage is minimized. The September 2003 Statement on the Recommended Use of Monoclonal Anti-RSV Antibody (Palivizumab) from the National Advisory Committee on Immunization (NACI) recommended that “If an entire vial (500 mg, 1 g) is not required for a patient's monthly injection, physicians should arrange for more than one patient to receive palivizumab within 6 hours in order to minimize product wastage”. It is noted that vial sharing is practiced in many jurisdictions and there is literature evidence to demonstrate cost savings associated with this practice.

The Ministry is aware that the total number of vials requested for any given clinic date may be less than the calculated number of vials based on total body weight of the infants due to sharing of vials. **The dose of palivizumab is 15 mg per kg of body weight.**

Clinics should not accumulate any extra vials at the end of the season to minimize the possibility of drug spoilage during the off-season (summer months) due to unforeseen circumstances.

**Canadian Paediatric Society Position Statement: Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health 2015;20(6):321-26**

The Ministry is aware of the opinions and recommendations of the Canadian Paediatric Society (CPS) position statement on the use of palivizumab which were released in September 2015. The Ministry is reviewing the Position Statement with advice from the Ontario RSV Advisory
Group, evaluating the available clinical and economic evidence for palivizumab and conducting a jurisdictional scan and discussions with provincial colleagues. Any changes or updates to the RSV criteria for the 2017-2018 season will be communicated by the end of this calendar year.

For further questions or clarifications on the Program policies and processes, please contact the Ministry at RSVProphylaxisProgram@ontario.ca or at 416-327-8109 or 1-866-811-9893. You may also refer to the ‘RSV Frequently Asked Questions’ document for more program information.

For questions on enrolment status, RSV season reference number, shipment order requests, and drug-related issues (ordering, shipment, storage, stability, administration), please contact the Synagis Coordinator at AbbVie Canada: 1-888-704-8270.

I trust that this information will be helpful in delivering this Program efficiently and effectively through the RSV season.

Original signed by

Sincerely,

Menzies Jardine
A/Director, Drug Programs Delivery Branch